Treace Medical Concepts (NASDAQ:TMCI) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Treace Medical Concepts (NASDAQ:TMCI) from a sell rating to a strong sell rating in a report published on Sunday.

A number of other equities research analysts have also commented on TMCI. Lake Street Capital decreased their price objective on Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. Stifel Nicolaus decreased their price objective on Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating for the company in a research report on Wednesday, January 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Treace Medical Concepts in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $4.77.

Treace Medical Concepts Stock Performance

Shares of NASDAQ TMCI opened at $1.94 on Friday. Treace Medical Concepts has a one year low of $1.17 and a one year high of $7.78. The firm has a market capitalization of $125.67 million, a PE ratio of -2.06 and a beta of 0.87. The company has a current ratio of 4.31, a quick ratio of 3.13 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $1.64 and a two-hundred day moving average price of $3.01.

Treace Medical Concepts (NASDAQ:TMCI) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15). Treace Medical Concepts had a negative return on equity of 59.91% and a negative net margin of 27.74%.The firm had revenue of $62.52 million during the quarter, compared to analyst estimates of $61.76 million. As a group, analysts predict that Treace Medical Concepts will post -0.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Treace Medical Concepts

Institutional investors have recently made changes to their positions in the company. CIBC Bancorp USA Inc. acquired a new stake in shares of Treace Medical Concepts during the 3rd quarter valued at about $122,199,000. Acuitas Investments LLC acquired a new stake in shares of Treace Medical Concepts during the 3rd quarter valued at about $2,020,000. William Blair Investment Management LLC lifted its holdings in shares of Treace Medical Concepts by 17.2% during the 3rd quarter. William Blair Investment Management LLC now owns 3,634,381 shares of the company’s stock valued at $24,387,000 after buying an additional 534,486 shares during the last quarter. First Eagle Investment Management LLC lifted its holdings in shares of Treace Medical Concepts by 36.4% during the 3rd quarter. First Eagle Investment Management LLC now owns 1,238,895 shares of the company’s stock valued at $8,313,000 after buying an additional 330,866 shares during the last quarter. Finally, Gagnon Advisors LLC lifted its holdings in shares of Treace Medical Concepts by 58.4% during the 4th quarter. Gagnon Advisors LLC now owns 1,534,034 shares of the company’s stock valued at $3,758,000 after buying an additional 565,570 shares during the last quarter. 84.08% of the stock is currently owned by institutional investors and hedge funds.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.